Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Catalent, Inc. CTLT NYSE

NYSE • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
44/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$74.25
+17%

Catalent, Inc. (CTLT) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $63.48. It has a SharesGrow Score of 44/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is CTLT = $74 (+17% upside).

Financials: revenue is $4.4B, +3.9%/yr average growth. Net income is $1.0B (loss), growing at -170.3%/yr. Net profit margin is -23.8% (negative). Gross margin is 21.8% (-12 pp trend).

Balance sheet: total debt is $4.9B against $3.6B equity (Debt-to-Equity (D/E) ratio 1.36, moderate). Current ratio is 2.52 (strong liquidity). Debt-to-assets is 50.4%. Total assets: $9.8B.

Analyst outlook: 8 / 21 analysts rate CTLT as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 30/100 (Fail), Past 50/100 (Partial), Health 50/100 (Partial), Moat 44/100 (Fail), Future 46/100 (Partial), Income 10/100 (Fail).

$74.25
▲ 16.97% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Catalent, Inc., the average price target is $74.25, with a high forecast of $132.00, and a low forecast of $41.00.
Highest Price Target
$132.00
Average Price Target
$74.25
Lowest Price Target
$41.00

CTLT SharesGrow Score Overview

44/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 44/100
Gross margin is + market cap
FUTURE 46/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — CTLT

✓
VALUE Pass
75/100
CTLT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $74, implying +16.6% from the current price $63. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
30/100
CTLT: +3.9%/yr revenue is, -170.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
CTLT: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet CTLT: Debt-to-Equity (D/E) ratio 1.36 (moderate), Current ratio is 2.52 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
44/100
CTLT: Gross margin is 21.8% (-12 pp trend), $12B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 44/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
46/100
Analyst outlook: 8 / 21 analysts rate CTLT as buy (38%). Analyst consensus target is $74 (+16.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
CTLT: Net profit margin is -23.8%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range42.11-63.5
Volume13.67M
Avg Volume (30D)2.27M
Market Cap$11.52B
Beta (1Y)1.16
Share Statistics
EPS (TTM)-5.76
Shares Outstanding$181M
IPO Date2014-07-31
Employees17,000
CEOAlessandro Maselli
Financial Highlights & Ratios
Revenue (TTM)$4.38B
Gross Profit$953M
EBITDA$-284M
Net Income$-1.04B
Operating Income$-749M
Total Cash$289M
Total Debt$4.92B
Net Debt$4.63B
Total Assets$9.75B
Price / Earnings (P/E)-11
Price / Sales (P/S)2.63
Analyst Forecast
1Y Price Target$63.50
Target High$132.00
Target Low$41.00
Upside+0.0%
Rating ConsensusHold
Analysts Covering21
Buy 38% Hold 57% Sell 5%
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS1488061029

Price Chart

Track all markets on TradingView
CTLT
Catalent, Inc. ↗  ·  NYSE
Healthcare • Drug Manufacturers - Specialty & Generic
42.11 52WK RANGE 63.50

People Also View

IQV
IQV
IQVIA Holdings Inc.
$175.28
+1.91%
 WST
WST
West Pharmaceutical Services, Inc.
$267.93
+3.07%
 CRL
CRL
Charles River Laboratories International, Inc.
$179.31
+0.54%
 BIO
BIO
Bio-Rad Laboratories, Inc.
$292.23
+1.41%
 TFX
TFX
Teleflex Incorporated
$125.21
+1.65%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message